Charles River Laboratories International, inc (CRL) Q2 2021 Earnings Call Transcript

Image source: The Motley Fool.

Charles River Laboratories International, inc (CRL -0.97%)
Q2 2021 Earnings Call
Aug 4, 2021, 9:30 a.m. ET

Contents:

• Prepared Remarks
• Questions and Answers
• Call Participants

Prepared Remarks:

Operator

Operator: Good day and thank you for standing by, and welcome to the Charles River Laboratories International Q2 2021 Earnings Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]

I would now like to hand the conference over to your host, Todd Spencer, Corporate Vice President of Investor Relations. Please go ahead.

Todd Spencer -- Corporate Vice President, Investor Relations

Thank you. Good morning, and welcome to Charles River Laboratories second quarter 2021 earnings conference call and webcast. This morning, Jim Foster, Chairman, President and Chief Executive Officer; and David Smith, Executive Vice President and Chief Financial Officer, will comment on our results for the second quarter of 2021. Following the presentation, they will respond to questions. There is a slide presentation associated with today's remarks, which is posted on the Investor Relations section of our website at ir.criver.com. A webcast replay of this call will be available beginning roughly two hours after the call today, and can also be accessed on our Investor Relations website. The replay will be available through next quarter's conference call. I'd like to remind you of our Safe Harbor. All remarks that we make about future expectations, plans and prospects for the company constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated.

During this call, we will primarily discuss non-GAAP financial measures, which we believe help investors gain a meaningful understanding of our core operating results and guidance. The non-GAAP financial measures are not meant to be considered superior to or a substitute for results from operations prepared in accordance with GAAP. In accordance with Regulation G, you can find the comparable GAAP measures and reconciliations on the Investor Relations section of our website.

I will now turn the call over to Jim Foster.

James C. Foster -- Chairman, President And Chief Executive Officer

Thanks, Todd. Good morning. The strength of our leading non-clinical portfolio was clearly demonstrated in our second quarter financial performance. Robust industry fundamentals are leading to unprecedented client demand across most of our businesses, and we're extremely well-positioned to succeed in this environment. Second quarter organic growth-revenue growth was in the mid-teens, even after normalizing for last year's COVID-19 impact and exceeded the long-term low double-digit target that we recently provided at our Investor Day in May. Clients are increasingly choosing to partner with us for our flexible and efficient outsourcing solutions, the scientific depth and breadth of our portfolio, and our unwavering focus on flawlessly serving the diverse needs. Utilizing our capabilities enables them to drive greater efficiency and accelerate the speed of their research, non-clinical development and manufacturing programs. We believe that the efforts we have made and continue to make to differentiate ourselves from the competition now critical as clients choose to work with a smaller number of CROs who offer broader scientific capabilities.

Due to the sustained demand, we are keenly focused on the execution of our strategy. We are strengthening our portfolio as we did through the acquisition of gene therapy CDMO, Vigene Biosciences in late June, strategically adding staff and capacity to accommodate the robust demand and support our clients and enhancing our digital enterprise to provide greater connectivity and exceptional service to them. We believe we will make these investments and remain well-positioned to achieve our operating margin target of 22.5% in 2024. We believe the success of our strategy is reflected in our second quarter performance. So let me provide some of the highlights. Quarterly revenue surpassed $900 million for the first time and a $914.6 million in the second quarter of 2021, represented a 34% increase over last year. Organic revenue growth of 24.1% was increased by approximately 8%, when compared to last year's COVID-19 impact in the second quarter of 2020, with the greatest impact in the Research Models and Services segment. Even after normalizing for the COVID impact, we reported mid-teens organic growth, with double-digit increases across all three business segments. The operating margin was 20.8%, an increase of 350 basis points year-over-year. The improvement was principally driven by the RMS segment, reflecting operating leverage from significantly higher sales volume for Research Models, due in part to the comparison to last year's COVID-19 impact. Notwithstanding this favorable year-over-year comparison, we were pleased with the margin progression in the first half of the year and are on track to achieve a full year operating margin of approximately 21% or 100 basis points higher than last year.

Earnings per share were $2.61 in the second quarter, an increase of 65.2% from $1.58 in the second quarter of last year. This result widely exceeded our prior outlook of more than 50% earnings growth for the quarter, primarily as a result of the exceptional demand environment. Based on the second quarter performance and our expectation for sustained demand through the remainder of the year, we are increasing our revenue growth and non-GAAP earnings per share guidance for 2021. We now expect organic revenue growth in a range of 13% to 15%, 100 basis point increase from our prior range. Non-GAAP earnings per share are expected to be in the range from $10.10 to $10.35, which represents 24% to 27% year-over-year growth and an increase of $0.35 at midpoint from our prior outlook. We attribute this exceptional performance and outlook to the success of our ongoing efforts to enhance our position as the leading non-clinical contract research and manufacturing organization, as well as the pace of scientific innovation that's fueling a significant increase in biotech funding and FDA approvals, both of which are tracking to near record levels through the first half of the year. I'd like to provide you with details on the second quarter segment performance, beginning with the DSA segment. Revenue was $540.1 million in the second quarter, an 18.1% increase on an organic basis over the second quarter of 2020, driven by broad-based demand for both Discovery and Safety Assessment Services. COVID only had a small impact on the DSA segment last year, so it wasn't a meaningful driver of the year-over-year growth.

Safety Assessment business continued to perform exceptionally well, reflecting robust demand from both biotech and global biopharma, clients and price increases. Bookings and proposal volume continued to achieve record highs in the second quarter, with strength across all regions and major service areas. The strength of biotech funding is enabling clients to meaningfully invest in early stage programs. And due to the unprecedented demand, we are now booking work into next year. As I mentioned last quarter, clients are expanding their preclinical pipelines and intensifying their focus on complex biologics to ensure they do not delay their research, we believe clients are securing space with us further in advance, which, in turn, provides us with greater visibility. To support our clients, we are continuing to add staff, capacity and the resources necessary to effectively manage the current demand environment and provide our clients with a timely, efficient and high-quality service that they have come to expect from Charles River. We believe these investments position Safety Assessment business well and will support low double-digit organic revenue growth in the DSA segment this year. We believe the combination of the robust funding environment as well as our deep scientific expertise and willingness to forge flexible relationships with our clients led to another exceptional quarter for the Discovery business.

Our comprehensive portfolio of oncology, CNS, early discovery and antibody discovery capabilities, which we recently enhanced through the Distributed Bio and Retrogenix acquisitions, is resonating with clients, and clients are increasingly choosing to outsource -- to integrated Discovery partners like Charles River. Despite the robust funding, biotech clients continue to maintain limited or no internal infrastructure, opting instead to invest in their pipelines and utilize our services to move their programs forward. To support the robust demand from biotech and global biopharmaceutical clients, we will continue to strengthen our portfolio by expanding our scale, our science and our innovative technologies through a combination of internal investment, M&A and our strategic partnership strategy. By doing so, we are enabling our clients to remain with one scientific partner from Target ID through IND filing and beyond and solidifying our position as the leading nonclinical CRO. The DSA operating margin increased by 30 basis points to 23.5% in the second quarter. Leverage from the robust DSA revenue growth was the primary driver of the margin improvement. Foreign exchange reduced the DSA operating margin by 150 basis points in the quarter as revenue and costs are not naturally hedged at certain DSA sites, including our Safety Assessment operations in Canada. We continue to expect the DSA margin will be in the mid-20% range for the year. RMS revenue was $176.7 million, an increase of 44.5% on an organic basis over the second quarter of 2020. Approximately 33.4% of this growth was attributable to the comparison to last year's COVID-related revenue impact from client site closures and disruptions, which reduced research model order activity.

Adjusted for the COVID impact, the RMS growth rate was above 10% as strong research activity across biopharmaceutical academic and government clients led most RMS businesses to grow above their targeted growth rates. Robust demand for research models in China continued to be the primary driver of RMS revenue growth. There has been a resurgence of research activity this year, and model volumes far exceed pre-COVID levels. Several other western markets, the client base in China has transitioned from one dominated by academic and government accounts to a vibrant mid-tier biotech and CRO client base, which now represents the majority of our clients in China. We believe the expansion of our client base is fueling increased demand. And to accommodate the growth, we are continuing to expand our model and services offering and our geographic and our geographic footprint in Western and Southern China. We are currently experiencing strong double-digit revenue growth in China. Demand for Research Models outside of China was also quite strong. We believe this correlates with the increased level of non-clinical research that's being conducted by biopharmaceutical and academic clients in Western markets. Research investments have led to biomedical breakthroughs and new drug modalities, and we believe the global focus on scientific innovation is sustainable. We also continue to win new academic clients in the second quarter, resulting from the COVID-19-related client shutdowns last year and more recently from digital engagements targeting the academic client base.

Research Model Services also performed very well. GEMS is benefiting from strong outsourcing demand as our clients seek the greater flexibility and efficiency they gain when we manage their proprietary model colonies. The greater complexity of scientific research and the proprietary models that our clients are creating further reinforce the value proposition for the GEMS business. Clients need for greater flexibility and efficiency is also driving demand for our Insourcing Solutions, or IS business, particularly for our CRADL initiative, which provides both small and large biopharmaceutical clients with turnkey research capacity at Charles River sites. In addition to expanding our existing CRADL presence and adding clients in the Boston, Cambridge and South San Francisco biohubs, we're also looking to expand into other regions to provide a flexible capacity solution for our clients in emerging biohubs. Utilizing CRADL also provides clients with collaborative opportunities to seamlessly access other Charles River services, which further enhances the speed and efficiency of their research programs. The revenue growth rate for our self-supply businesses, HemaCare and Cellero, improved in the second quarter, but remain below the targeted level due to continued limitations on donor access. We believe cell supply revenue will increase during the second half of the year as donor availability and capacity improved.

We have expanded capabilities, including donor capacity at our cell supply sites in Massachusetts and Washington State, which we believe will enable us to further expand our donor base in the US and accommodate the robust demand in the broader cell therapy market. We expect HemaCare and Cellero will provide the critical tools for our new cell and gene therapy CDMO business, Cognate and Vigene. We believe this will be highly synergistic for both Charles River and our clients because it will enable us to move client cell therapy programs forward using the same cellular products from research to CGMP production. The RMS operating margin increased to 27.4% from 9.1% in the second quarter of last year. The significant improvement was primarily due to the comparison to last year's depressed margin associated with COVID-related client disruptions and the corresponding reduction in Research Model order activity. Revenue for the Manufacturing segment was $197.8 million, a 26.6% increase on an organic basis over the second quarter of last year. The increase was driven by strong double-digit revenue growth in both the Biologics Testing Solutions and Microbial Solutions businesses.

COVID-19 did not have a meaningful impact on the segment's revenue last year, but testing on COVID vaccine -- COVID-19 vaccines has helped accelerate Biologics revenue growth rate this year. Consistent with the first quarter, Microbial Solutions growth rate in the second quarter was well above the 10% level, reflecting strong demand for our Endosafe Endotoxin testing systems, cartridges, and core reagents in all geographic regions, as well as Accugenix microbial identification services. With COVID related client access restrictions effectively behind us, we were pleased with the strength of the underlying demand for our endotoxin testing platform, which reforms FDA mandated lot release testing for our clients' critical quality control testing needs. The advantages of our comprehensive portfolio continue to resonate with clients, and we believe that our ability to provide a total microbial testing solution will enable Microbial Solutions to deliver at least low double-digit organic revenue growth this year and beyond, which is consistent with the historical trend pre-COVID. The Biologics Testing business reported another exceptional quarter of strong revenue growth that was well above the 20% growth target for this business. Robust demand for cell and gene therapy testing services continue to be the primary growth driver. There has been a rapid increase in the number of cell and gene therapy programs in development to approximately 3,000 programs now in the pipeline, with approximately two-thirds in the preclinical phase, which is expected to continue to fuel the strong growth.

COVID-19 vaccine work was also a meaningful driver of Biologics second quarter growth, but the underlying Biologics growth trends remained above the 20% level, even without the incremental COVID-19 testing revenue. We believe cell and gene therapies will continue to be significant growth drivers over the long-term, and demand for COVID-19 vaccine testing is showing no signs of abating. We believe the commercial production of COVID vaccines will continue for many years to come, supporting the demand for our services. These factors are contributing to the strength of the demand environment, and we continue to build our extensive portfolio of manufacturing services to ensure we have available capacity to accommodate client demand. The Manufacturing segment second quarter operating margin declined by 420 basis points to 33.2%. The primary driver of the decline primary driver of the decline was the addition of Cognate's CDMO business as well as higher production costs in the Microbial business. Cognate is a profitable business with a solid operating margin, but its margin is below the Manufacturing segment. Coupled with the addition of Vigene in the third quarter, we expect a full year Manufacturing margin slightly below the mid-30% range. However, beyond 2021, we expect this headwind to gradually dissipate as we drive efficiency and as the significant growth we anticipate generates greater economies of scale and optimizes throughout our CDMO sites.

Early in the second quarter, Cognate BioServices officially joined Charles River, followed by Vigene Biosciences in late June. We were very pleased to welcome both teams to the company. Aligned with HemaCare and Cellero, these businesses form the core of our cell and gene therapy offering, and we believe they will be highly complementary to our Biologics business and our portfolio as a whole. We are pleased with the initial progress on the integrations and the addition of the cell and gene therapy CDMO services to a comprehensive portfolio, which is resonating with clients. Our clients are beginning to explore opportunities to streamline their biologics development workflows by using Cognate's and Vigene's services, and their legacy clients are already looking to utilize other products and services within the Charles River portfolio to drive greater efficiency in their development and manufacturing activities. We believe the acquisition of Vigene Biosciences with its viral vector-based gene delivery solutions, fulfills our objective to create a comprehensive cell and gene therapy portfolio, which spans each of the major CDMO platforms. Gene-modified cell therapy, viral vector and plasmid DNA production. In combination with Cognate's Memphis-based operations, we have established an end-to-end gene-modified cell therapy solution in the US, which we believe is critical to support our clients more seamlessly. Our goal is to enable clients to conduct analytical testing, process development and manufacturing for these advanced modalities, with the same scientific partner, enabling them to achieve their goal of driving greater efficiency and accelerating the speed to market.

As a result of the successful execution of our strategy to date, we believe that our portfolio is the strongest it has ever been. Our efforts to enhance our scientific capabilities, deliver flexible outsourcing solutions and provide greater value to our clients have made Charles River an important partner for our clients. With the biopharmaceutical industry benefiting from record funding levels, we are experiencing robust demand for our essential products and services. To support this demand and to continue to enhance the value we provide to clients, we will continue to move our growth strategy forward. Acquisitions and strategic partnerships remain vital components of our strategy, as we endeavor to expand the scientific expertise, global reach and innovative technologies that we can offer clients across all three of our business segments. Investing in our scientific capabilities as well as internally on the necessary staff resources in our digital enterprise will help us ensure that we can meet the needs of our clients. The successful execution of our strategy will not only enable us to enhance our position as our clients' partner of choice from concept to nonclinical development to the safe manufacture of their life-saving therapeutics. It will also allow us to achieve our longer-term financial targets of low double-digit organic revenue growth and an average of approximately 50 basis points of operating margin improvement beyond 2021. In conclusion, I'd like to thank our clients and shareholders for their support and our employees for their exceptional work and commitment.

And now, I'll ask David to give you additional details on our second quarter results and updated 2021 guidance.

David R. Smith -- Corporate Executive Vice President And Chief Financial Officer

Thank you, Jim, and good morning. Before I begin, may I remind you that I'll be speaking primarily to non-GAAP results, which exclude amortization and other acquisition-related charges, costs related primarily to our global efficiency initiative, our venture capital and other strategic investment performance and certain advances. Many of our comments will also refer to organic revenue growth, which excludes the impact of acquisitions and foreign currency translation. Once again, we are very pleased with another strong performance in the second quarter. Robust revenue and earnings-per-share growth outperformed our prior outlook. Organic revenue growth of 24.1%, including 8% related to last year's COVID-19 impact and operating margin expansion of 350 basis points, were the primary drivers behind earnings-per-share growth share growth of 65.2% to $2.61. These results also reflect a favorable comparison to the second quarter of last year in which we experienced the peak of the COVID-related impact and client disruptions.

Based on our strong second quarter results and expectations for the underlying strength of demand to continue, we have increased our full year financial guidance and now expect to deliver organic revenue growth in a range of 13% to 15% for the full year. Primarily as a result of the enhanced growth prospects this year, and to a lesser extent, a favorable tax rate, we raised our earnings per share guidance by $0.35 to a range of $10.10 to $10.35, which represents year-over-year growth of 24% to 27%. By segment, our updated outlook for 2021 reflects the strong business environment. For RMS, we continue to expect organic revenue growth in the high teens, driven by the Recovery in Research Model order activity from the impact of the COVID-19 pandemic last year, as well as exceptional growth in China.

Our outlook for DSA is unchanged, with low double-digit organic revenue growth for the full year, reflecting continued strength in early stage research activity. For the Manufacturing segment, we now expect to achieve high-teens organic revenue growth. Our revised outlook is based on exceptionally strong demand in Biologics, driven primarily by cell and gene therapy programs and an increase in contribution from the Microbial Solutions business, which is expected to return to at least low double-digit growth for the full year. Including the acquisitions of Cognate and, more recently, Vigene Biosciences, Manufacturing's reported revenue growth rate is expected to be in the low to mid-40% range.

With regard to operating margin, our expectations for segment contributions remain mostly unchanged from our prior outlook, with the RMS operating margin meaningfully above 25% for the full year, DSA in the mid-20% range and Manufacturing slightly below the prior mid-30% outlook, principally reflecting the addition of Vigene in late June. Lower unallocated corporate costs contributed to the second quarter margin expansion, totaling 5.6% of revenue or $51.2 million in the second quarter, compared to 6.1% of revenue last year. Our scalable infrastructure enables us to drive greater efficiencies even as we continue to make investments to support the growth of our businesses and meet the needs of our clients. We continue to expect unallocated corporate costs to be in the mid-5% range as a percentage of revenue for the full year.

The second quarter non-GAAP tax rate was 20.4%, representing a 60 basis point decline from 21% in the second quarter of last year. The decrease was due to a favorable excess tax benefit associated with stock-based compensation, which resulted from increased equity exercise and award activity at higher stock price levels during the quarter. This benefit was partially offset by higher tax expense associated with the UK tax law change. or the full year, we are reducing our tax rate outlook to a range of 19.5% to 20.5% from our prior outlook of a tax rate in the low 20% range, principally driven by a higher benefit from stock-based compensation. Total adjusted net interest expense for the second quarter was $20.8 million, an increase of $3.7 million sequentially and $1.7 million year-over-year, due to higher debt balances primarily to fund the Cognate acquisition. At the end of the second quarter, we had an outstanding debt balance of $2.7 billion, representing gross and net leverage ratios of about 2.5 times.

Subsequent to the end of the second quarter, we completed the acquisition of Vigene on June 28. On a pro forma basis, including Vigene, our gross leverage ratio remained below three times, which we attribute to our robust free cash flow generation that has enabled us to repay debt ahead of our expectations. For the full year, we now expect total adjusted net interest expense to be slightly below our prior outlook in a range of $82 million to $85 million, primarily reflecting the accelerated debt repayment. Free cash flow was $140.2 million in the second quarter, an increase of 3.5% over the $135.5 million for the same period last year. The primary drivers of the increase were our strong second quarter operating performance and distributions from our VC investments, partially offset by higher capital expenditures. In view of our robust results in the first half of the year, we have increased our free cash flow outlook by $65 million and now expect free cash flow of approximately $500 million for the full year. capex was $46.4 million in the second quarter last year, compared to $26.8 million last year. The increase was due primarily to the timing of projects.

Some investments, which were slowed or deferred during the COVID-19 disruptions last year are now back on track. We continue to expect capex to be approximately $220 million for the full year. A summary of our revised financial guidance for the full year, including all recent acquisitions, can be found on slide 39. For the third quarter, our outlook reflects a continuation of the strong demand environment. We do expect that growth rates will normalize from the second quarter levels, because we have anniversarized the peak of the COVID-19-related revenue loss last year.

Accordingly, we expect organic revenue growth in the low to mid-teens range and reported revenue growth in the low 20% range. You should note that we are not forecasting a meaningful difference between the first half and second half organic growth rate after normalizing last year's COVID impact, which is not surprising as we believe the robust demand environment is showing no signs of abating. We expect low double-digit earnings-per-share growth when compared to last year's third quarter level of $2.33. I will remind you that the DSA operating margin in the third quarter of last year included a 50 basis point benefit from a discovery milestone payment, which will impact the year-over-year comparison.

In closing, we are very pleased with our second quarter results, which included another quarter of robust revenue, earnings and free cash flow growth. We continue to be focused on the continued execution of our strategy and achieving our financial and operational targets, which will move us forward toward our longer-term targets for 2024. Thank you.

Todd Spencer -- Corporate Vice President, Investor Relations

That concludes our comments. Operator, we will now take questions.

Questions and Answers:

Operator

[Operator Instructions] And your first question comes from the line of Eric Coldwell with Baird.

Eric Coldwell -- Baird -- Analyst

Thank you. Good morning. Main question is on preclinical Safety Assessment. We are hearing in our various channel checks that sites are booked well into 2022. I know you made a comment on that in your call. We're hearing that more broadly. We're also hearing that some of your competitors have been placing massive long-term model purchase commitments, multiyear commitments, very large, which I think is a sign of the strength of the industry, but it really comes down to the question of capacity and where you stand, what kind of investments you're making, how do you balance this supply demand imbalance so your clients don't try to seek other solutions in the marketplace. Just any thoughts on that would be helpful.

James C. Foster -- Chairman, President And Chief Executive Officer

Yes, Eric. We're investing capacity thoughtfully, aggressively, geographically, multiple sites at once, not dissimilar to what we've done historically. We're continually reviewing where we think the demand will be for the next few years and ensuring that our capacity needs are-that our capacity is sufficient to accommodate that. I don't think it's a bad thing that clients are reserving space earlier, which allows us to plan better, obviously, gives us greater visibility from a staffing and expense point of view.

It also provides a more orderly business model, frankly. And it's not all that dissimilar to the way it was years ago, where we had similar types of demand even though the client base was quite different. So where I'd say, the principal conversations around here are ensuring-working hard and ensuring that we have sufficient headcount and physical capacity to accommodate the demand, not just in Safety, by the way. Obviously, Safety is our biggest business. So principally, the conversation goes there, but certainly across Biologics and Discovery and other businesses-and certainly China and RMS as well. We're thrilled focusing on ensuring that we have sufficient capacity. It's what we put this portfolio together for to service the clients as they outsource more work. So we are very much on top of that, Eric.

Eric Coldwell -- Baird -- Analyst

Okay. Jim, if I could squeeze one more in.

James C. Foster -- Chairman, President And Chief Executive Officer

Yeah.

Eric Coldwell -- Baird -- Analyst

I noticed in the press release a comment about higher production costs in Microbials. I was hoping to get a little more color on that.

James C. Foster -- Chairman, President And Chief Executive Officer

Yeah. Nothing really significant. Just certain raw material costs are kind of higher at the moment of supply chain issues that lots of businesses are having. Things that's quite transitory. Margin is still quite good in that business, and the growth rate really was terrific. So just kind of short-term blip.

Eric Coldwell -- Baird -- Analyst

Okay. Thanks very much. Good job with the quarter.

James C. Foster -- Chairman, President And Chief Executive Officer

Sure. Thanks, Eric.

Operator

Your next question comes from the line of Tycho Peterson with JPMorgan.

Tycho Peterson -- JPMorgan -- Analyst

Hey, good morning. I'll start with a question on Manufacturing. On the back of the Vigene deal, you noted clients are beginning to explore opportunities to streamline development with you. I guess as you look at your cell and gene therapy portfolio today are there any existing gaps? And can you talk a little bit more about how Vigene fits in with the rest of that business?

James C. Foster -- Chairman, President And Chief Executive Officer

Yeah. I think it's a pretty solid portfolio, Tycho. We have the cells, which, for cell therapy, obviously, there is no cell therapy R&D or scale up without that. So we like that we start first with that. We now have significant capability in cell therapy manufacturing, particularly modified cell therapies. And we have this viral vector and plasma DNA capability in both sides of the pond now, US and Europe, which give us a substantial capability as well. There maybe some nuances. And of course, we're always looking at M&A opportunities. So I don't want to get too specific, except to say that I think that M&A would be principally around in just increased scale and enhanced geographic dispersion and diversity and growth. I do think that not unlike other businesses, geographic proximity, particularly when you're dealing with live cells is not unimportant and would be beneficial, and clients still like the ability to be relatively close to their external providers of services, if possible. So there's still a fair number of assets out there that we're quite interested in there, a variety of sizes. I'd say most of them are on the smaller side. Some larger ones we may have wanted, but those are no longer available.

If we are unable, for whatever reason or unwilling because of the price point, to buy any of the targets we currently have, I think we do have a very -- we have a terrific installed base, and the growth rates will be such that will become a big business. And of course, just want to remind you that we look at the cell and gene therapy assets, which are whatever it is, now 18 to 24 months old. We look at those very much in combination with our Biologics business, which is very high growth right now. You heard us talk about north of 20%. Terrific capacity here. Those businesses are joined that they have for the testing of those cell and gene therapy products before they go into the clinic. And hopefully, after they're approved, before they go into patients, will be just as essential as the contract manufacturing pieces of it. So we're thrilled to be able to piece those together. Pretty big portfolio now. I think that we didn't update it on this call, but I think we said our cell and gene therapy revenues are greater than 10% of total Charles River. It's a big number, and it's going to grow disproportionately fast. So very pleased with the portfolio.

Tycho Peterson -- JPMorgan -- Analyst

All right. And then a follow-up on RMS. Obviously, a number of those businesses benefited over the past year from the challenges around the pandemic. If you look at the GEMS outsourcing and also the CRADL insourcing initiatives. I guess as we're kind of passed the halfway point part of this year and working through getting back to labs up and running, how do you feel about the durability of some of those trends, in particular around GEMS and CRADL insourcing?

James C. Foster -- Chairman, President And Chief Executive Officer

Really good. While we certainly got and are enjoying enhanced outsourcing from clients that did work themselves or didn't use us or used us partially, and we really proved the value proposition that we have by staying open and doing this great work. The -- but putting aside that COVID pop as it were, this significant demand -- increasing demand for GEMS models -- specialty models and more complex models and more translational models for sure, this IS business is increasingly more interesting. The CRADL -- these CRADL locations in -- principally in Cambridge, Mass and South San Francisco and eventually other important parts of the world are both high-revenue generators, high-margin businesses and significant feeders to other parts of our business, particularly service enterprises. So being in those environments, being part of the Cambridge sort of Kendall Square universe has been critically important to us. So I think the growth rates margin contributions are absolutely sustainable in those businesses, and we will continue to expand capacity, both in the current places that we are located, but also we're going to add new sites as well.

Tycho Peterson -- JPMorgan -- Analyst

Okay. Thank you.

James C. Foster -- Chairman, President And Chief Executive Officer

Sure.

Operator

Next, we have a question from the line of Dave Windley with Jefferies.

Dave Windley -- Jefferies -- Analyst

Close enough, I guess. Good morning. Thanks for taking my question. I wanted to, Jim, ask about China, tie a couple of things together there. You mentioned that the demand in China has kind of rotated from the academic and government sector to more private sector client base. I'd be curious your comments about how that influences your price points and margins for your business in China? And then the second part of my question would be, given the success there in models and the evolution and strength in investment in biopharma in China in general, is it time just to rethink or start thinking about planting other business lines in China to leverage off of your existing base?

James C. Foster -- Chairman, President And Chief Executive Officer

Yes. So huge investment by the Chinese government in the life sciences, venture capital firms are plenty. And so, we're seeing significant investment in sort of classic and new pharma companies and mostly biotech companies. So while I don't personally think the market will overtake the US, I think it's going to be the second largest market for sure. Yes, I mean, provides enormous demand for us. I think, look, we'll always try to get more price. It's a general proposition, including in China. So I wouldn't say otherwise. You know that the cost structure is significantly lower than other parts of the world as the price points, but the margins are comparable. We have to be careful given the fact that we have lower -- we have a lot of local Chinese competitors who I think are, in part or in whole, financed by the government. And so they have the ability to really go after us always on price, just like we've seen in the US and Europe. I mean our RMS competitors worldwide principally compete with us on price and not so much on quality or service.

But having said that, we'll continue to drive price as much as we can because, of course, costs go up in China as well. And of course, we've -- we're growing at least the RMS franchise very nicely. So, lots of investments in services, IS, GEMS, etc., lab testing, rehabs in China and significant investments in new production facilities. Your second question is a tough one to answer. So I'll just remind you, we have a large and growing RMS business. We have a -- we actually have a large Microbial business. It's just that since the testing isn't regulated over there, the total revenue contribution is relatively modest. And we have months, done sort of a joint venture in our Biologics business, which we're pretty excited about because we have many of our major competitors over there.

I think as a general proposition, we would like to do everything we do in China, and we certainly would like to do Discovery and Safety. And as we've said catalyst times, M&A multiples are a real deterrent for us. I mean there's no way we can rationally buy companies over there to build out our portfolio without crushing our returns. So, we're not going to do that. So, the issue for us is when do we want to enter and how do we do that thoughtfully and fiscally responsibly with sort of a JV type thing like we've done with Biologics, that's always a possibility and/or greenfield, our activities there, which is it's slower, which we wouldn't like to that. It's obviously a little less by than buying a company, but it's not insignificant. We're just going to have to continue to evaluate the market demand. I would tell you that we are so busy, as you know, from our numbers in the US and Europe that we have lots of work and great growth rates and escalating operating margins without the complexity and some of the challenges of doing work in China. So we're not particularly frustrated with it right now. I would say it's a longer term strategic conversation that we're having all the time within Charles River.

Dave Windley -- Jefferies -- Analyst

That's very helpful. Thank you, Jeff.

James C. Foster -- Chairman, President And Chief Executive Officer

Sure, it's-Sure, Dave.

Operator

Your next question comes from the line of John Kreger with William Blair.

John Kreger -- William Blair -- Analyst

Hi. Thanks very much. Jim, my question relates to the capacity availability for Cognate and Vigene. Can you just remind us where those programs are in terms of their capacity build-out? Should we be assuming a necessary step-up in capex in the next couple of years? Or is that already sort of in the long-term plan?

James C. Foster -- Chairman, President And Chief Executive Officer

Definitely in our guidance. So what we've told you about the accretion of those businesses to our top line to our EPS and improving operating margins is real. Both of those businesses have a significant amount of available capacity. By that, I mean they were in the process of expanding capacity when we bought for both of them were actually. So that will continue. It's a significant amount of space. It's an interesting one, John, that the business is so potentially so explosive. The ability to take clients, particularly in the manufacturing pieces, the pure CDMO piece for biotype cell therapies, to take those from clinical production to commercial, which we can see with a couple of the clients, at least, depending on how impactful those new drugs are will lead up a lot of capacity.

So we're just going to have to live through it. We're going to always have to have incremental capacity available. By that, I mean, rent space, have a plan to finish it either all at once or in slices, sort of chunk it out there and stay very close to the clients, how the drugs are doing, what phase they're in, how well financed are they, what's the competitive scenario. And we're doing that really well. So I think we're in a very good place right now as we see capacity for the next, I don't know, a couple of years, but we're going to have to stay ahead of it. The guidance that we gave recently about we anticipate that capex will be around 7% of our revenue, that incorporates and accommodates for significant growth certainly in Safety, certainly in Discovery and certainly in the CDMO business, which is obviously, a new business for us.

I don't think it's particularly more capital-intensive than lots of other things that we do. And I know that -- and particularly the at the cell therapy type of work that we're doing is -- I'm not saying it's not capital-intensive, but it's not as intensive as some other aspects of the CDMO space. So we think we have our arms around sort of scale, growth and cost.

John Kreger -- William Blair -- Analyst

Sounds great. Thank you.

Operator

Next question comes from the line of Elizabeth Anderson with Evercore.

Elizabeth Anderson -- Evercore -- Analyst

Hi, guys. Thanks so much for the question. I was wondering if you could expand on Tycho's question a little bit and sort of talk more about the cross-sell opportunity in cell and gene therapy between RMS and the CDMO business so far, sort of where are you in terms of the interest of clients to sort of do the whole spectrum with you? And sort of how do you see that progressing over the next few years? Thanks.

James C. Foster -- Chairman, President And Chief Executive Officer

Yeah. I mean we see it progressing well. If you look at just -- if you look certainly at most of our large clients, I would say that they buy most and some by everything that we sell, all our products and all of our services. So we are increasingly more important provider, significant spend with those companies. We're dealing with very senior people there, and they look at us as an essential provider of a whole bunch of things that they need. The smaller clients get, particularly our biotech clients, while many of them are pre-revenue, lots of them are public, and they put $10 billion or $15 billion or $20 billion market caps. So they're not small companies, and they have -- while they may have the money, they have no, as I said in my prepared remarks, zero desire to build these things out internally. And I think that's going to get increasingly more nuanced, that they're going to have less of a desire, particularly in things like cell and gene therapy or Biologics Testing, or for sure, Safety.

So the broader the portfolio, I think the more client capture that we have. We're already seeing almost immediately, as I commented on briefly in my remarks, clients who were working with Cognate and Vigene interested in the broader range of services that Charles River has and conversely clients that were working with Charles River are very interested that we now have the cell and gene therapy capabilities. So everything is about speed to market with all of these companies regardless of their size and the ability to work as much -- do as much as possible with a single source to kind of get the pricing behind you and not have to renegotiate every step of the way definitely accelerates the whole process.

Also with some of these small companies, our regulatory capability is really helpful to them to kind of guide them for their FDA filings or filings with other regulatory agencies around the world. So given the fact that there are 3,000 cell and gene therapy drugs in development, two-thirds of which are in preclinical, hopefully, a large number of which we are already working with and will continue to work with having these capabilities was really essential for us to participate in a really large portion of the marketplace.

Elizabeth Anderson -- Evercore -- Analyst

Got it. That's really helpful. Thanks.

Operator

Your next question comes from the line of Juan with Bank of America.

Juan Avendano -- Bank of America -- Analyst

Hi. Thank you for the question. Regarding your margin targets in 2021 and 2024, what would you say is the likelihood or risk the Manufacturing support margins could remain in the low 30s given the investments that need to take place in this area? And how do you see the negative impact of foreign exchange and DSA margins playing out for the rest of this year and in relation to your 2024 margin target?

David R. Smith -- Corporate Executive Vice President And Chief Financial Officer

Okay. I'll take that, Jim. So I'll take the FX one on DSA to start. So you've seen 150 basis point headwind in DSA for Q2. It basically averages out just around about 100 basis points for the first half of the year. And actually, we actually think the second half of the year would be somewhat similar. That said, in respect to your question about how the FX might turn out in the longer term, as we've seen through history, we should see that reverse. I can't predict when that FX will reverse. But at some point, we should see some benefits coming in certainly over the period to 2024. In respect to the question around the CDMO drag on the margins, and in particular, Cognate, we -- well, to start, we're not expecting to see a meaningful impact on the consolidated operating margin. But to your question, yes, there is a drag on the Manufacturing segment's margin.

And as we said before, we expect to see modest margin improvement over the next few years. And as we deliver the acquisition synergies, there's -- we've got a great procurement department. We've got good back-office functions that can bring some synergies to those businesses. We will continue to enhance the scale of the business. And like we do with every operating unit, we're looking to drive operating efficiency. And with the high revenue growth where we're expecting north of 25% for the foreseeable future, we would get economies as those, you feel like, the fixed costs become less prevalent with respect to the whole business.

So in terms of margin progression, we would expect to see with time the manufacturing business improve, certainly, from today's position. And in terms of long-term guidance that we gave just two months ago, we did say that we were expecting to get into the mid-30% range. Clearly, we will do what we can to improve that further. But at this stage, we're posting over the next year's mid-30s for Manufacturing.

Juan Avendano -- Bank of America -- Analyst

Thank you.

Operator

Your next question is from the line of Donald Hooker with KeyBanc.

Donald Hooker -- KeyBanc -- Analyst

Great. Good morning. Was curious if you all could elaborate a bit on any potential inflationary pressures. Obviously, tremendous demand for what you're doing. I'm wondering if it might be more expensive to hire the scientific talent now than it was before. Are you seeing any trends there? How do you manage that?

James C. Foster -- Chairman, President And Chief Executive Officer

Take that, David?

David R. Smith -- Corporate Executive Vice President And Chief Financial Officer

Yes, I'll answer that. So well, I'll take the broader question first on just wage and inflation pressures. I mean like many people you picked up that many companies, it's a global issue, pressures across most industries, I can't say heavy industry, but certainly most of industries and regions and certainly wage pressure recruitment for charter has been an always in terms of, you know, we're continually growing and we got to keep up with that, we've spoken about this many of our earnings calls you know we've discussed some of the investments that we've made and initiatives to address that in the past like the living wage, work life balance initiatives and so on. And yes, we're seeing our revenue growth is ahead of our initial expectations. So as you can imagine, we're working very hard in multiple geographies to actually make sure we're hiring and meeting that robust demand. So really, the -- to your question about splitting that between workgroups, it's more about bringing in the staff or the sort of the wider growth that we're seeing as opposed to specific categories. Of course, with 19,000 people, there's going to be some departments where we may feel that there are some needs to pay more to make sure that we can get that type of result in.

But we're not seeing a blanket issue with respect to scientific staff or with other staff. It's more about just managing the shear growth within Charles River, vis-a-vis the wider churn that we're seeing in the wider economy. Because of COVID, people -- many people are looking for change. So we continue to drive some of these work-life balance type issues because that will go a long way to helping with retention as well. But notwithstanding all that, that I've described, we've factored that into the guidance for this year. We still feel that, that's still relevant in respect to the longer-term guidance that we've given. So we should still see that 150 basis point increase over the next three years after this year. How that will pan out within the years, too early to call. But certainly, we feel with the extra growth that we're benefiting from, that helps pay for some of these global issues that we're all facing.

Donald Hooker -- KeyBanc -- Analyst

Great. Thank you.

Operator

Your next question comes from the line of Patrick Donnelly with Citi.

Patrick Donnelly -- Citi -- Analyst

Hey, thanks for taking questions guys. Jim, maybe just on kind of that increased demand in the backlog going out until next year. Can you just talk a little bit about the pricing environment? Are you seeing clients book on things like take-or-pay basis, just the reserve space when they need it? And what kind of pricing are you guys kind of talking about in some of these bookings in the out years?

James C. Foster -- Chairman, President And Chief Executive Officer

No take-or-pay yet. Frankly surprises me. If I was in the client's shoes, I would do that just to protect myself, so I could go to the front of the line and not have to get in line. But that's their business and their call. So every once in a while, we get a quasi serious question about that. So what would that look like? And we give them a quote, and I guess it's too expensive. We're really pleased with the price. Again, we're not going to disclose the price, we haven't for years, but we're really pleased with the pricing that we're getting in Safety. With the studies continue to be incredibly complex, more complex they used to be, oftentimes, endpoints are added as the drug progresses and looks more promising, those studies get more expensive.

And we continue to have a nice mix between what we call general toxicology and special toxicology, which provides an enhancement to the overall price paradigm. We have to be conscious and cognizant and professional about the pricing because not unlike so many of our other businesses, like RMS, for instance, we have competitors, particularly smaller ones that compete with us principally on price, allegedly on speed and flexibility, which is not true. I'd like to play the card that Charles River must be too slow because it's so big. That's just not true.

So -- and when we have new opportunities to build on new work unless we're trying to take work from our competitor, but pretty much always driving the price up. So I would say that pricing is increasingly -- it's certainly an important focus of our clients. But I would say as demand has intensified and as capacity continues to fill, even with new capacity being built, that price is not the first thing the clients talk about, and I think it's provided some opportunities for us. We've been pretty pleased with the pricing yields for the last, I'd say, three years anyway. And I wouldn't anticipate any change in that going forward.

Patrick Donnelly -- Citi -- Analyst

Got it. Thanks, Jim.

James C. Foster -- Chairman, President And Chief Executive Officer

Sure.

Operator

There are no other questions at this time.

Todd Spencer -- Corporate Vice President, Investor Relations

Great. Well, thank you for joining us on the conference call this morning. We look forward to speaking with you during an upcoming investor conference. This concludes the call.

Operator

[Operator Closing Remarks]

Duration: 60 minutes

Call participants:

Todd Spencer -- Corporate Vice President, Investor Relations

James C. Foster -- Chairman, President And Chief Executive Officer

David R. Smith -- Corporate Executive Vice President And Chief Financial Officer

Eric Coldwell -- Baird -- Analyst

Tycho Peterson -- JPMorgan -- Analyst

Dave Windley -- Jefferies -- Analyst

John Kreger -- William Blair -- Analyst

Elizabeth Anderson -- Evercore -- Analyst

Juan Avendano -- Bank of America -- Analyst

Donald Hooker -- KeyBanc -- Analyst

Patrick Donnelly -- Citi -- Analyst

More CRL analysis

All earnings call transcripts